The pharmaceutical sector, mirroring the dynamic nature of diseases it combats, requires constant adaptation. Committed to innovation and expansion, our focus remains on chronic diseases, bolstering operational efficiency, and global reach. Recent strategic initiatives drive productivity-led growth in our India operations. Portfolio optimization, refined market segmentation, and targeted campaigns enhance our market presence. Establishing a dedicated division for high-growth therapeutic segments and branding our active pharmaceutical ingredients as Alkem Activa highlights our proactive leadership and global expansion approach.

Our leadership in the domestic acute segment, upheld by flagship brands like Clavam, Pan, Pan D, A to Z, Uprise D3 and Taxim-O, showcases our adeptness in seizing market opportunities with precision. This is evidenced by our Vitamins/Minerals/Nutrients (VMN) and Gastro-intestinal outperforming IPM growth. Additionally, our robust performance in the chronic segment during FY 2023-24, surpassing IPM growth in key therapeutic areas such as Anti-diabetic and Cardiac therapies underscores our success. In 2023, our milestones included the introduction of Cetuxa, a biosimilar of Cetuximab, illustrating our commitment to scientific innovation. At the same time, our entry into Ophthalmology reflects our dedication to meeting diverse patient needs. Additionally, our expansion into Contract Development and Manufacturing Organisation (CDMO) services in the US demonstrates our strategic vision.

Balancing short-term growth objectives with long-term resilience, we navigate the intricacies of the market with agility, ensuring a trajectory of sustained progress and innovation. As we embark on our exploration into the medical devices sector, guided by our core values of integrity and innovation, we stand poised to redefine the future of healthcare.